The hyperinflammatory phase represents the main cause for the clinical worsening of acute
respiratory distress syndrome (ARDS) in Coronavirus disease 2019 (COVID-19), leading to …

(1) Objectives: Patients with COVID-19 infection have been given various formulations and
dosages of steroids over the last year and a half. This study aims to compare the effects of …

Background: The COVID-19 pandemic has led to millions of deaths throughout the world.
Several randomized controlled trials have demonstrated that steroids reduce mortality in …

Intro Dexamethasone, a corticosteroid, was recently demonstrated to be the only medication
capable of reducing mortality in severe COVID disease in the UK's Recovery Trial. There is a …

Objective In this study, we aimed to compare the effects of intravenous dexamethasone and
methylprednisolone on the treatment of inpatients with COVID-19. Methods In this …

(1) Background: Data on different steroid compounds for the treatment of hospitalized
COVID-19 (coronavirus disease 2019) patients are still limited. The aim of this study was to …

Background: COVID-19 disease is caused by severe acute respiratory syndrome corona
virus 2 (SARS-CoV-2). In the first half of 2020 COVID-19 disease has already converted into …

Objective: COVID-19 is associated with lung damage and a high mortality rate in
hospitalised patients. Corticoids may reduce the evolution to respiratory failure and death …

Intro The RECOVERY trial showed evidence that dexamethasone given at moderate doses
for a short period of time reduced mortality in comparison to standard of care in hospitalised …

Aims: Our study aimed to compare the effect of a standard dose (SD) of MPS (60–120
mg/day) to a high dose (HD) of MPS (> 120 mg/day) on the outcome of hospitalized COVID …